Managing atrial fibrillation in chronic and end-stage kidney disease means balancing thrombotic and bleeding risk against an evidence base full of gaps. This session opens with the risk prediction tools available in CKD/ESKD and what they mean for care, then examines how those risks translate into real-world anticoagulation decisions for patients with kidney disease and atrial fibrillation. It closes by asking whether left atrial appendage occlusion devices offer a genuine alternative when anticoagulation itself carries too much risk, weighing their benefits and limitations in this population.
| Time | Session |
|---|---|
|
14:00
14:22
|
Calculating risk, changing care: risk prediction and its implications in CKD/ESKD
|
|
14:22
14:45
|
Anticoagulation in atrial fibrillation and kidney disease: a decision without an easy answer
Wolfgang Winkelmayer
Speaker
|
|
14:45
15:07
|
An alternative to anticoagulation? Left atrial appendage devices and their risk-benefit in kidney disease
Lim Choon Pin
Speaker
|
|
15:07
15:30
|
Q&A
|